Emil Lou is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 609 publications with 7,054 citations (h-index 40); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2450 Riverside Ave
Minneapolis, MN 554541450
Telephone
612-672-6000Provider last certified this registry record 8 Jan 2024.
Clinical trials
- CISH Inactivated TILs in the Treatment of NSCLC
Sponsor: Intima Bioscience, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20253 payments
- Novocure Inc.Program year20222 payments
- Novocure Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
55.6%Phenothiazine55.6%Prochlorperazine Maleate100%Part D≥11 patientsSensory organs
44.4%Corticosteroid44.4%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
American Society of Clinical Oncology Educational Book
2024 - Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
International Journal of Radiation Oncology*Biology*Physics
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”